Frank Vinluan The FDA has approved an off-the-shelf cell therapy from Gamida Cell that makes life-saving treatment more widely available to patients with certain blood cancers. The new therapy could also help overcome some of the racial disparities that persist in accessing such treatments. The regulatory decision announced Monday covers the treatment of patients 12 and older with blood cancers intended to be treated by an umbilical cord transplant. The Gamida Cell therapy, which was known in development as omidubicel, will be marketed under the brand name “Omisirge.”...